The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pulmonary fibrosis
Publications
Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk.
Seminars in arthritis and rheumatism 2010 Oct;40;147-63 — 2010 Oct — 147-63
Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, Elvin K, Crow MK, Nennesmo I, Lundberg IE
A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.
Annals of the rheumatic diseases 2008 Dec;67;1670-7 — 2008 Dec — 1670-7
[TNF blockade in rheumatoid arthritis can cause severe fibrosing alveolitis. Six case reports].
Lakartidningen 2005 Dec 5-11;102;3788-90, 3793 — 2005 Dec 5-11 — 3788-90, 3793
Severe interstitial pneumonitis associated with infliximab therapy.
Scandinavian journal of rheumatology 2004;33;276-7 — 2004 — 276-7